Metabolic reprogramming in cancer cells: Glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer

World Journal of Surgical Oncology

Volumn 14, Issue 1, 2016, Pages

  Li, Chunxia ^a   Zhang, Guifeng ^a   Zhao, Lei ^a   Ma, Zhijun ^a   Chen, Hongbing ^a  

^a YIDU CENTRAL HOSPITAL OF WEIFANG   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BIM PROTEIN; CITRIC ACID; CYCLIN DEPENDENT KINASE 5; DIHYDROXYACETONE PHOSPHATE; GLUCOSE; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; GLYCEROPHOSPHATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTIC ACID; MALIC ACID; MONOCARBOXYLATE TRANSPORTER; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXALOACETIC ACID; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; PYRUVIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

AMINO ACID METABOLISM; CANCER CELL; CELL METABOLISM; CITRIC ACID CYCLE; GLUTAMINOLYSIS; GLYCOLYSIS; LYSIS; MITOCHONDRION; NUCLEAR REPROGRAMMING; NUCLEOTIDE METABOLISM; PENTOSE PHOSPHATE CYCLE; PROTEIN FUNCTION; REVIEW; APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GLUTAMINE; GLYCOLYSIS; HUMANS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84954410074     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-016-0769-9     Document Type: Review

References (60)

1. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519-30.
2. Hanahan D, Weinberg R. The hallmarks of cancer. Cell. 2000;100:57-70.
3. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;44:646-74.
4. Moussaieff A, Rouleau M, Kitsberg D, Cohen M, Levy G, Barasch D, et al. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab. 2015;21:392-402.
5. Folmes C, Dzeja P, Nelson T, Terzic A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell. 2012;11:596-606.
6. Lehninger A, Nelson D, Cox M. Principles of biochemistry. 2nd ed. New York: Worth; 1993.
7. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269-70.
8. LeBleu V, O'Connell J, Gonzalez Herrera K, Wikman H, Pantel K, Haigis M, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16:992-1003.
9. Salem A, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti M. Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle. 2012;11:4174-80.
10. Slavov N, Budnik B, Schwab D, Airoldi E, van Oudenaarden A. Constant growth rate can be supported by decreasing energy flux and increasing aerobic glycolysis. Cell Rep. 2014;7:705-14.
11. van Dijken J, Weusthuis R, Pronk J. Kinetics of growth and sugar consumption in yeasts. Antonie Van Leeuwenhoek. 1993;63:343-52.
12. Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230-3.
13. Rodríguez-Enríquez S, Gallardo-Pérez J, Avilés-Salas A, Marín-Hernández A, Carreño-Fuentes L, Maldonado-Lagunas V, et al. Energy metabolism transition in multi-cellular human tumor spheroids. J Cell Physiol. 2008;216:189-97.
14. Holmsen H, Storm E. The adenosine triphosphate inhibition of the pyruvate kinase reaction and its dependence on the total magnesium ion concentration. Biochem J. 1969;112:303-16.
15. Vora S, Oskam R, Staal G. Isoenzymes of phosphofructokinase in the rat. Demonstration of the three non-identical subunits by biochemical, immunochemical and kinetic studies. Biochem J. 1985;229:333-41.
16. Grahame Hardie D. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med. 2014;276:543-59.
17. Woods A, Johnstone S, Dickerson K, Leiper F, Fryer L, Neumann D, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol. 2003;13:2004-8.
18. Zhao R, Xu Z. Targeting the LKB1 tumor suppressor. Curr Drug Targets. 2014;15:32-52.
19. Faubert B, Vincent E, Griss T, Samborska B, Izreig S, Svensson R, et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci U S A. 2014;111:2554-9.
20. Shackelford D, Abt E, Gerken L, Vasquez D, Seki A, Leblanc M, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013;23:143-58.
21. Ishijima N, Kanki K, Shimizu H, Shiota G. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib. Cancer Sci. 2015;106(5):567-75. doi: 10.1111/cas[Epub ahead of print].
22. Wang Y, Liu W, He X, Fei Z. Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK. Cell Biochem Biophys. 2015;71:701-6.
23. Christofk H, Vander Heiden M, Wu N, Asara J, Cantley L. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452:181-6.
24. Luo WSG. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 2012;23:560-6.
25. Anastasiou D, Yu Y, Israelsen W, Jiang J, Boxer M, Hong B, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8:839-47.
26. Parnell K, Foulks J, Nix R, Clifford A, Bullough J, Luo B, et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol Cancer Ther. 2013;12:1453-60.
27. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425-34.
28. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997;94:6658-63.
29. Yao Y, Wang H, Li B. LDH5 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis. Tumour Biol. 2014;35:6973-81.
30. Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem. 2010;17:672-97.
31. Gao P, Tchernyshyov I, Chang T, Lee Y, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762-5.
32. Miranda-Goncalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol. 2013;15:172-88.
33. Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queiros O, Preto A, et al. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol. 2014;29:1511-24.
34. Newsholme E, Crabtree B, Ardawi M. The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci Rep. 1985;5:393-400.
35. DeBerardinis R, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104:19345-50.
36. Wise D, DeBerardinis R, Mancuso A, Sayed N, Zhang X, Pfeiffer H, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105:18782-7.
37. Kim S, Yoo Y, Lee J, Park J. Mitochondrial NADP(+)-dependent isocitrate dehydrogenase knockdown inhibits tumorigenicity of melanoma cells. Biochem Biophys Res Commun. 2014;451:246-51.
38. Reitman Z, Duncan C, Poteet E, Winters A, Yan L, Gooden D, et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J Biol Chem. 2014;289:23318-28.
39. Losman J, Kaelin WJ. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836-52.
40. Saha S, Parachoniak C, Ghanta K, Fitamant J, Ross K, Najem M, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513:110-4.
41. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340:622-6.
42. Emadi A, Jun S, Tsukamoto T, Fathi A, Minden M, Dang C. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol. 2014;42:247-51.
43. Seltzer M, Bennett B, Joshi A, Gao P, Thomas A, Ferraris D, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70:8981-7.
44. Gross A, McDonnell J, Korsmeyer S. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-911.
45. Czabotar P, Lessene G, Strasser A, Adams J. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49-63.
46. Reed J, Zha H, Aime-Sempe C, Takayama S, Wang H. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol. 1996;406:99-112.
47. Kelekar A, Thompson C. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998;8:324-30.
48. Tait S, Green D. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621-32.
49. Zimmermann K, Bonzon C, Green D. The machinery of programmed cell death. Pharmacol Ther. 2001;92:57-70.
50. Lomonosova E, Chinnadurai G. BH3-only proteins in apoptosis and beyond: an overview. Oncogene. 2008;27 Suppl 1:S2-19.
51. Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008;27 Suppl 1:S149-57.
52. Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677-81.
53. Lessene G, Czabotar P, Colman P. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989-1000.
54. Danial N, Gramm C, Scorrano L, Zhang C, Krauss S, Ranger A, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 2003;424:952-6.
55. Winter P, Sarosiek K, Lin K, Meggendorfer M, Schnittger S, Letai A, et al. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal. 2014;7:ra122.
56. Sastry K, Al-Muftah M, Li P, Al-Kowari M, Wang E, Ismail Chouchane A, et al. Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells. Cell Death Differ. 2014;21:1936-49.
57. Chang C, Shen C, Su H, Chen C. Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation. J Neurooncol. 2011;105:507-22.
58. Lowman X, McDonnell M, Kosloske A, Odumade O, Jenness C, Karim C, et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol Cell. 2010;40:823-33.
59. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013;24:499-511.
60. Lin H, Chen M, Chiu C, Song Y, Lin S. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J Biol Chem. 2007;282:2776-84.